Natco Pharma to launch generic Risdiplam after court win

Natco Pharma Limited will immediately launch its generic version of Risdiplam at an MRP of INR 15,900, following the Commercial Appellate Division of the Delhi High Court's dismissal of an appeal filed by F. Hoffmann-La Roche AG on October 9, 2025. This decision overturns an earlier appeal from April 8, 2025, and upholds the single judge's ruling from March 24, 2025, which denied Roche's injunction plea, citing public interest and the inaccessibility of the original drug's pricing. The ruling removes the final hurdle for Natco to offer an affordable alternative for Spinal Muscular Atrophy (SMA) treatment.

In a separate announcement on October 9, 2025, Natco Pharma also appointed G. Vijay Kiran Kumar as vice president – corporate quality assurance (Formulations), effective the same day. Kumar, an experienced quality assurance professional with over 24 years in the pharmaceutical industry, was previously associated with Dr. Reddy’s Laboratories Limited as plant head. This appointment aligns with the company's strategic focus on expanding its pharmaceutical offerings.